Rhenium–platinum antitumor systems
This review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium(III) compounds and their synergism with cisplatin. In particular, we describe the work of the rhenium-platinum antitumor system (introduction of rhenium and platinum c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry
2017-04-01
|
| Series: | The Ukrainian Biochemical Journal |
| Online Access: | http://ukrbiochemjournal.org/wp-content/uploads/2017/04/Stemenko_2_17.pdf |
| _version_ | 1797641749036793856 |
|---|---|
| author | A. V. Shtemenko N. I. Shtemenko |
| author_facet | A. V. Shtemenko N. I. Shtemenko |
| author_sort | A. V. Shtemenko |
| collection | DOAJ |
| description | This review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium(III) compounds and their synergism with cisplatin. In particular, we describe the work of the rhenium-platinum antitumor system (introduction of rhenium and platinum compounds). Among known metal-based anticancer drugs and drug candidates dirhenium(III) compounds differ profoundly due to their strong antiradical and antioxidant properties determined by quadruple bond unsaturation. Such advantages of metal complexes as more expressed redox chemical propertie should be exploited for creating more efficient anticancer drugs. Combination of drugs leads to synergistic effects and/or to lowering toxicity of platinides and is very promising in cancer chemotherapy. The review covers the following items: design of quadruple bonded dirhenium(III) clusters, their spectral and antiradical properties (in short); interaction of the dirhenium(III) compounds with lipids and formation of liposomes; interaction of the dirhenium(III) compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia; anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system; antianemic and antioxidant properties of the dirhenium(III) compounds in the model of tumor growth; interaction of the dirhenium(III) compounds with nucleobases and DNA. Some modern trends in the field of bioinorganic and medicinal chemistry are also considered regarding their connection to the rhenium-platinum system efficiency: use of combinational therapy and nanomaterials; involvement of some biologically active ligands and redox-activation strategy, etc. |
| first_indexed | 2024-03-11T13:50:06Z |
| format | Article |
| id | doaj.art-579169003c5e45f0b0555be1d216defa |
| institution | Directory Open Access Journal |
| issn | 2409-4943 2413-5003 |
| language | English |
| last_indexed | 2024-03-11T13:50:06Z |
| publishDate | 2017-04-01 |
| publisher | National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry |
| record_format | Article |
| series | The Ukrainian Biochemical Journal |
| spelling | doaj.art-579169003c5e45f0b0555be1d216defa2023-11-02T09:10:47ZengNational Academy of Sciences of Ukraine, Palladin Institute of BiochemistryThe Ukrainian Biochemical Journal2409-49432413-50032017-04-0189253010.15407/ubj89.02.005Rhenium–platinum antitumor systemsA. V. Shtemenko0N. I. Shtemenko1Ukrainian State University of Chemical Technology, Dnipro, UkrainePalladin Institute of Biochemistry, National Academy of Sciences of Ukraine, KyivThis review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium(III) compounds and their synergism with cisplatin. In particular, we describe the work of the rhenium-platinum antitumor system (introduction of rhenium and platinum compounds). Among known metal-based anticancer drugs and drug candidates dirhenium(III) compounds differ profoundly due to their strong antiradical and antioxidant properties determined by quadruple bond unsaturation. Such advantages of metal complexes as more expressed redox chemical propertie should be exploited for creating more efficient anticancer drugs. Combination of drugs leads to synergistic effects and/or to lowering toxicity of platinides and is very promising in cancer chemotherapy. The review covers the following items: design of quadruple bonded dirhenium(III) clusters, their spectral and antiradical properties (in short); interaction of the dirhenium(III) compounds with lipids and formation of liposomes; interaction of the dirhenium(III) compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia; anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system; antianemic and antioxidant properties of the dirhenium(III) compounds in the model of tumor growth; interaction of the dirhenium(III) compounds with nucleobases and DNA. Some modern trends in the field of bioinorganic and medicinal chemistry are also considered regarding their connection to the rhenium-platinum system efficiency: use of combinational therapy and nanomaterials; involvement of some biologically active ligands and redox-activation strategy, etc.http://ukrbiochemjournal.org/wp-content/uploads/2017/04/Stemenko_2_17.pdf |
| spellingShingle | A. V. Shtemenko N. I. Shtemenko Rhenium–platinum antitumor systems The Ukrainian Biochemical Journal |
| title | Rhenium–platinum antitumor systems |
| title_full | Rhenium–platinum antitumor systems |
| title_fullStr | Rhenium–platinum antitumor systems |
| title_full_unstemmed | Rhenium–platinum antitumor systems |
| title_short | Rhenium–platinum antitumor systems |
| title_sort | rhenium platinum antitumor systems |
| url | http://ukrbiochemjournal.org/wp-content/uploads/2017/04/Stemenko_2_17.pdf |
| work_keys_str_mv | AT avshtemenko rheniumplatinumantitumorsystems AT nishtemenko rheniumplatinumantitumorsystems |